Results 21 to 30 of about 3,958 (169)

Synthesis of β‐ 3 H‐mitotane for use in a rapid assay for mitotane metabolism [PDF]

, 1995
A 3 H + ‐release method has been developed for the assay of β‐hydroxylation of the adrenolytic drug mitotane. β‐ 3 H‐mitotane was synthesized by the reduction of 1‐(2‐chlorophenyl)‐1‐(4‐chlorophenyl)‐2,2,2‐trichloroethane by an aluminium‐Hg 2 Cl 2 ...
Counsell, Raymond E., Sinsheimerl, Joseph E., Raymond E. Counsell, David E. Schteingart, Piñeiro‐sánchez, Mayra L., Schteingart, David E., Vaz, Alfin D. N., Mayra L. Piñeiro‐Sánchez, Ruyan, Mohamed K., Alfin D. N. Vaz, Mohamed Ruyan, Joseph E. Sinsheimerl   +11 more
core   +1 more source

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures [PDF]

, 2020
CONTEXT: Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and deal with severe toxicity, marking the relevance of predictive parameters for treatment outcome. OBJECTIVE: Determine the effects of mitotane in primary ACC cultures,
Herder, W.W. (Wouter) de, Dogan, F. (Fadime), Creemers, S.G. (Sara), Hofland, Leo; id_orcid, Koetsveld, P.M. (Peter) van, de Herder, W.W., Feelders, R.A., Creemers, SG (Sara), Feelders, R.A. (Richard), van Koetsveld, Peter, Dogan - Oruç, Fadime, Franssen, Gaston, Hofland, Leo, Hofland, L.J. (Leo), Franssen, G. (Gaston)   +14 more
core   +2 more sources

Adrenocortical Carcinoma in Peutz-Jeghers Syndrome With a Rare STK11 Pathogenic Germline Variant: A Case Report. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Peutz–Jeghers syndrome (PJS) is an inherited, autosomal‐dominant condition, featuring STK11 germline mutations, characterized by hamartomatous gastrointestinal polyps and increased cancer risk. The most commonly associated malignancies are gastrointestinal, pancreatic, and breast cancers.
Ishida T, Kandori S, Takahashi R, Nitta S, Shiga M, Nagumo Y, Kawahara T, Hoshi A, Negoro H, Mathis BJ, Sugita S, Matsubara D, Ishiguro T, Nakajima T, Nishiyama H.   +14 more
europepmc   +2 more sources

Adjuvant mitotane treatment for adrenocortical carcinoma. [PDF]

, 2007
Background Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant treatment has been controversial.
CONTON PA, M. Fassnacht, DAFFARA F, S. Hahner, Daffara, F, B. Ambrosi, BUCI L, REIMONDO G, PAPOTTI M, TAUCHMANOVA L, TERZOLO M, GROSSRUBATSCHER E, E. Arvat, P. Sperone, F. Daffara, Angeli, A, G. Reimondo, MANTERO, FRANCO, Reimondo, Giuseppe Matteo, M. Papotti, AMBROSI B, SAEGER W, MANNELLI M, L. Buci, FASSNACHT M, M. Terzolo, P. Loli, A. C. Koschker, ANGELI A, Papotti, Mauro Giulio, G. Lombardi, BERRUTI, Alfredo, L. Tauchmanova, E. Grossrubatscher, HAHNER S, ALLOLIO B, Arvat, Emanuela, A. Angeli, R. Rossetto, ANGELI, PAOLO, LOLI P, Terzolo, Massimo, ARVAT E, W. Saeger, M. Ma, BRUZZI P, LOMBARDI G, DOGLIOTTI L, E. Bollito, ROSSETTO R, KOSCHKER AC, SPERONE P, BOLLITO E, BERRUTI A., P. A. Conton, MANTERO F   +55 more
core   +1 more source

Editorial Comments to Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study. [PDF]

Int J Urol
International Journal of Urology, Volume 33, Issue 1, January 2026.
Morozumi K.
europepmc   +2 more sources

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma

Life, 2021
(1) Background: In clinical settings, data regarding sex are rarely investigated. In women, factors such as body size and composition, hormonal variations, metabolism, and access to care systems and therapy could strongly influence the pharmacological ...
Sarah Allegra, Soraya Puglisi, Irene Brescia, Francesco Chiara, Vittoria Basile, Anna Calabrese, Giuseppe Reimondo, Silvia De Francia   +7 more
doaj   +1 more source

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study

Frontiers in Endocrinology, 2023
ObjectiveHypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied.
Andrea Delbarba, Deborah Cosentini, Paolo Facondo, Marta Laganà, Letizia Chiara Pezzaioli, Valentina Cremaschi, Andrea Alberti, Salvatore Grisanti, Carlo Cappelli, Alberto Ferlin, Alfredo Berruti   +10 more
doaj   +1 more source

Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma

Endocrinology, Diabetes & Metabolism Case Reports, 2023
Mitotane is used for treatment of advanced adrenocortical carcinoma. It is administered when the carcinoma is unresectable, metastasized, or at high-risk of recurrence after resection.
Sandra Martens, Bruno Lapauw
doaj   +1 more source

Conventional and novel strategies in the treatment of adrenocortical cancer

Brazilian Journal of Medical and Biological Research, 2000
Adrenocortical carcinoma is a highly malignant neoplasm with an incidence of two per million people per year. Several treatment strategies have resulted in temporary or partial tumor regression but very few cases have attained long survival.
D.E. Schteingart
doaj   +1 more source

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report

Frontiers in Oncology, 2023
Adrenocortical carcinoma (ACC) is a rare, heterogeneous, and aggressive malignancy with a generally poor prognosis. Surgical resection is the optimal treatment plan.
Jianhua Deng, Lihui Wei, Qihuang Fan, Zoey Wu, Zhigang Ji   +4 more
doaj   +1 more source